O	0	9	Treatment	Treatment	NN	B-NP
O	10	13	for	for	IN	B-PP
O	14	22	patients	patient	NNS	B-NP
O	23	27	with	with	IN	B-PP
O	28	36	diabetes	diabetes	NN	B-NP

O	37	39	It	It	PRP	B-NP
O	40	42	is	be	VBZ	B-VP
O	43	50	notable	notable	JJ	B-ADJP
O	51	55	that	that	IN	B-SBAR
O	56	65	treatment	treatment	NN	B-NP
O	66	68	of	of	IN	B-PP
O	69	77	diabetes	diabetes	NN	B-NP
O	78	81	has	have	VBZ	B-VP
O	82	85	not	not	RB	I-VP
O	86	90	been	be	VBN	I-VP
O	91	99	directly	directly	RB	I-VP
O	100	109	monitored	monitor	VBN	I-VP
O	110	112	by	by	IN	B-PP
O	113	117	OECD	OECD	NN	B-NP
O	118	128	indicators	indicator	NNS	I-NP
O	128	129	,	,	,	O
O	130	137	largely	largely	RB	B-ADJP
O	138	141	due	due	JJ	I-ADJP
O	142	144	to	to	TO	B-PP
O	145	155	complexity	complexity	NN	B-NP
O	156	158	in	in	IN	B-PP
O	159	163	data	datum	NNS	B-NP
O	164	174	collection	collection	NN	I-NP
O	174	175	.	.	.	O

O	176	185	Treatment	Treatment	NN	B-NP
O	186	188	is	be	VBZ	B-VP
O	189	197	tailored	tailor	VBN	I-VP
O	198	201	for	for	IN	B-PP
O	202	213	individuals	individual	NNS	B-NP
O	214	223	depending	depend	VBG	B-PP
O	224	226	on	on	IN	B-PP
O	227	230	the	the	DT	B-NP
O	231	238	patient	patient	NN	I-NP
O	238	239	'	'	POS	B-NP
O	239	240	s	s	NN	I-NP
O	241	248	disease	disease	NN	I-NP
O	249	255	status	status	NN	I-NP
O	255	256	,	,	,	O
O	257	260	and	and	CC	O
O	261	266	plays	play	VBZ	B-VP
O	267	268	a	a	DT	B-NP
O	269	276	crucial	crucial	JJ	I-NP
O	277	281	role	role	NN	I-NP
O	282	284	in	in	IN	B-PP
O	285	293	diabetes	diabetes	NN	B-NP
O	294	304	management	management	NN	I-NP
O	304	305	.	.	.	O

O	306	314	Clinical	Clinical	JJ	B-NP
O	315	321	trials	trial	NNS	I-NP
O	322	326	have	have	VBP	B-VP
O	327	332	found	find	VBN	I-VP
O	333	337	that	that	IN	B-SBAR
O	338	339	a	a	DT	B-NP
O	340	343	one	one	CD	I-NP
O	344	354	percentage	percentage	NN	I-NP
O	355	360	point	point	NN	I-NP
O	361	370	reduction	reduction	NN	I-NP
O	371	373	in	in	IN	B-PP
O	374	379	HbA1c	HbA1c	NN	B-NP
O	380	386	levels	level	NNS	I-NP
O	387	392	would	would	MD	B-VP
O	393	399	reduce	reduce	VB	I-VP
O	400	405	micro	micro	AFX	B-NP
O	405	406	-	-	HYPH	I-NP
B-Multi-tissue_structure	406	414	vascular	vascular	JJ	I-NP
O	415	428	complications	complication	NNS	I-NP
O	429	431	by	by	IN	B-PP
O	432	434	25	25	CD	B-NP
O	434	435	%	%	NN	I-NP
O	436	438	to	to	TO	I-NP
O	439	441	30	30	CD	I-NP
O	441	442	%	%	NN	I-NP
O	443	444	[	[	(	O
O	444	446	49	49	CD	B-NP
O	446	447	,	,	,	I-NP
O	447	449	50	50	CD	I-NP
O	449	450	]	]	)	O
O	451	454	and	and	CC	O
O	455	456	a	a	DT	B-NP
O	457	459	10	10	CD	I-NP
O	460	464	mmHg	mmHg	NN	I-NP
O	465	474	reduction	reduction	NN	I-NP
O	475	477	in	in	IN	B-PP
B-Organism_substance	478	483	blood	blood	NN	B-NP
O	484	492	pressure	pressure	NN	I-NP
O	493	498	would	would	MD	B-VP
O	499	507	decrease	decrease	VB	I-VP
O	508	513	macro	macro	AFX	B-NP
O	513	514	-	-	HYPH	I-NP
O	515	518	and	and	CC	I-NP
O	519	524	micro	micro	AFX	I-NP
O	524	525	-	-	HYPH	I-NP
B-Multi-tissue_structure	525	533	vascular	vascular	JJ	I-NP
O	534	547	complications	complication	NNS	I-NP
O	548	551	and	and	CC	O
O	552	557	death	death	NN	B-NP
O	558	563	rates	rate	NNS	I-NP
O	564	566	by	by	IN	B-PP
O	567	569	32	32	CD	B-NP
O	569	570	%	%	NN	I-NP
O	571	572	[	[	(	O
O	572	574	51	51	CD	B-NP
O	574	575	]	]	)	O
O	575	576	.	.	.	O

O	577	585	Improved	Improve	VBN	B-VP
O	586	593	control	control	NN	B-NP
O	594	596	of	of	IN	B-PP
B-Organism_substance	597	602	blood	blood	NN	B-NP
O	603	609	lipids	lipid	NNS	I-NP
O	610	613	can	can	MD	B-VP
O	614	620	reduce	reduce	VB	I-VP
O	621	625	risk	risk	NN	B-NP
O	626	628	of	of	IN	B-PP
B-Multi-tissue_structure	629	637	coronary	coronary	JJ	B-NP
B-Organ	638	643	heart	heart	NN	I-NP
O	644	651	disease	disease	NN	I-NP
O	652	654	by	by	IN	B-PP
O	655	657	39	39	CD	B-NP
O	657	658	%	%	NN	I-NP
O	659	662	and	and	CC	O
O	663	667	risk	risk	NN	B-NP
O	668	670	of	of	IN	B-PP
O	671	676	death	death	NN	B-NP
O	677	679	by	by	IN	B-PP
O	680	682	43	43	CD	B-NP
O	682	683	%	%	NN	I-NP
O	684	685	[	[	(	O
O	685	687	52	52	CD	B-NP
O	687	688	]	]	)	O
O	688	689	.	.	.	O

O	690	694	RAND	RAND	NN	B-NP
O	694	695	'	'	''	O
O	695	696	s	s	VBZ	B-VP
O	697	704	Quality	Quality	NNP	B-NP
O	705	715	Assessment	Assessment	NNP	I-NP
O	716	721	Tools	Tools	NNP	I-NP
O	722	728	System	System	NNP	I-NP
O	729	735	offers	offer	VBZ	B-VP
O	736	746	indicators	indicator	NNS	B-NP
O	747	755	relating	relate	VBG	B-VP
O	756	758	to	to	TO	B-PP
O	759	767	diabetes	diabetes	NN	B-NP
O	768	777	treatment	treatment	NN	I-NP
O	778	779	[	[	(	O
O	779	781	53	53	CD	B-NP
O	781	782	]	]	)	O
O	782	783	,	,	,	O
O	784	787	and	and	CC	O
O	788	799	application	application	NN	B-NP
O	800	802	of	of	IN	B-PP
O	803	808	these	these	DT	B-NP
O	809	819	indicators	indicator	NNS	I-NP
O	820	822	in	in	IN	B-PP
O	823	824	a	a	DT	B-NP
O	825	833	national	national	JJ	I-NP
O	834	839	study	study	NN	I-NP
O	840	842	in	in	IN	B-PP
O	843	846	the	the	DT	B-NP
O	847	849	US	US	NNP	I-NP
O	850	853	has	have	VBZ	B-VP
O	854	862	provided	provide	VBN	I-VP
O	863	870	insight	insight	NN	B-NP
O	871	875	into	into	IN	B-PP
O	876	885	adherence	adherence	NN	B-NP
O	886	888	to	to	TO	B-PP
O	889	900	recommended	recommend	VBN	B-NP
O	901	910	treatment	treatment	NN	I-NP
O	911	919	regimens	regimen	NNS	I-NP
O	919	920	.	.	.	O

O	921	924	For	For	IN	B-PP
O	925	931	people	people	NNS	B-NP
O	932	936	with	with	IN	B-PP
O	937	942	newly	newly	RB	B-NP
O	943	952	diagnosed	diagnose	VBN	I-NP
O	953	961	diabetes	diabetes	NN	I-NP
O	962	964	56	56	CD	B-NP
O	964	965	%	%	NN	I-NP
O	966	974	received	receive	VBD	B-VP
O	975	982	dietary	dietary	JJ	B-NP
O	983	986	and	and	CC	I-NP
O	987	995	exercise	exercise	NN	I-NP
O	996	1007	counselling	counselling	NN	I-NP
O	1007	1008	.	.	.	O

O	1009	1011	In	In	IN	B-PP
O	1012	1016	type	type	NN	B-NP
O	1017	1018	2	2	CD	I-NP
O	1019	1027	diabetes	diabetes	NN	I-NP
O	1028	1036	patients	patient	NNS	I-NP
O	1036	1037	,	,	,	O
O	1038	1041	use	use	NN	B-NP
O	1042	1044	of	of	IN	B-PP
B-Organism_subdivision	1045	1049	oral	oral	JJ	B-NP
O	1050	1063	hypoglycaemic	hypoglycaemic	JJ	I-NP
O	1064	1070	agents	agent	NNS	I-NP
O	1071	1074	for	for	IN	B-PP
O	1075	1080	those	those	DT	B-NP
O	1081	1093	inadequately	inadequately	RB	B-VP
O	1094	1104	controlled	control	VBN	I-VP
O	1105	1107	on	on	IN	B-PP
O	1108	1115	dietary	dietary	JJ	B-NP
O	1116	1123	therapy	therapy	NN	I-NP
O	1124	1127	was	be	VBD	B-VP
O	1128	1130	38	38	CD	B-NP
O	1130	1131	%	%	NN	I-NP
O	1132	1135	and	and	CC	O
O	1136	1139	use	use	NN	B-NP
O	1140	1142	of	of	IN	B-PP
O	1143	1150	insulin	insulin	NN	B-NP
O	1151	1154	for	for	IN	B-PP
O	1155	1160	those	those	DT	B-NP
O	1161	1173	inadequately	inadequately	RB	B-VP
O	1174	1184	controlled	control	VBN	I-VP
O	1185	1187	on	on	IN	B-PP
B-Organism_subdivision	1188	1192	oral	oral	JJ	B-NP
O	1193	1207	hypoglycaemics	hypoglycaemic	NNS	I-NP
O	1208	1211	was	be	VBD	B-VP
O	1212	1214	39	39	CD	B-NP
O	1214	1215	%	%	NN	I-NP
O	1215	1216	.	.	.	O

O	1217	1222	Fifty	Fifty	CD	B-NP
O	1222	1223	-	-	HYPH	I-NP
O	1223	1227	five	five	CD	I-NP
O	1228	1235	percent	percent	NN	I-NP
O	1236	1238	of	of	IN	B-PP
O	1239	1248	diabetics	diabetic	NNS	B-NP
O	1249	1253	were	be	VBD	B-VP
O	1254	1261	offered	offer	VBN	I-VP
O	1262	1264	an	an	DT	B-NP
O	1265	1268	ACE	ACE	NN	I-NP
O	1269	1278	inhibitor	inhibitor	NN	I-NP
O	1279	1285	within	within	IN	B-PP
O	1286	1287	3	3	CD	B-NP
O	1288	1294	months	month	NNS	I-NP
O	1295	1297	of	of	IN	B-PP
O	1298	1301	the	the	DT	B-NP
O	1302	1310	notation	notation	NN	I-NP
O	1311	1313	of	of	IN	B-PP
B-Organism_substance	1314	1325	proteinuria	proteinuria	NN	B-NP
O	1326	1332	unless	unless	IN	B-SBAR
O	1333	1348	contraindicated	contraindicate	VBN	B-VP
O	1348	1349	.	.	.	O

O	1350	1353	The	The	DT	B-NP
O	1354	1361	AusDiab	AusDiab	NNP	I-NP
O	1362	1367	study	study	NN	I-NP
O	1368	1376	reported	report	VBD	B-VP
O	1377	1380	the	the	DT	B-NP
O	1381	1390	treatment	treatment	NN	I-NP
O	1391	1398	pattern	pattern	NN	I-NP
O	1399	1404	among	among	IN	B-PP
O	1405	1415	Australian	Australian	JJ	B-NP
O	1416	1422	adults	adult	NNS	I-NP
O	1423	1427	with	with	IN	B-PP
O	1428	1432	type	type	NN	B-NP
O	1433	1434	2	2	CD	I-NP
O	1435	1443	diabetes	diabete	NNS	I-NP
O	1444	1445	[	[	(	O
O	1445	1447	37	37	CD	B-NP
O	1447	1448	]	]	)	O
O	1448	1449	.	.	.	O

O	1450	1455	While	While	IN	B-SBAR
O	1456	1458	32	32	CD	B-NP
O	1458	1459	%	%	NN	I-NP
O	1460	1462	of	of	IN	B-PP
O	1463	1471	diabetes	diabetes	NN	B-NP
O	1472	1480	patients	patient	NNS	I-NP
O	1481	1485	were	be	VBD	B-VP
O	1486	1488	on	on	IN	B-PP
O	1489	1493	diet	diet	NN	B-NP
O	1494	1501	regimen	regimen	NN	I-NP
O	1502	1506	only	only	RB	B-ADVP
O	1506	1507	,	,	,	O
O	1508	1510	58	58	CD	B-NP
O	1510	1511	%	%	NN	I-NP
O	1512	1516	used	use	VBN	B-VP
B-Organism_subdivision	1517	1521	oral	oral	JJ	B-NP
O	1522	1535	hypoglycaemic	hypoglycaemic	JJ	I-NP
O	1536	1542	agents	agent	NNS	I-NP
O	1543	1546	and	and	CC	O
O	1547	1551	diet	diet	NN	B-NP
O	1552	1556	only	only	RB	B-ADVP
O	1556	1557	,	,	,	O
O	1558	1561	and	and	CC	O
O	1562	1569	another	another	DT	B-NP
O	1570	1572	10	10	CD	I-NP
O	1572	1573	%	%	NN	I-NP
O	1574	1578	took	take	VBD	B-VP
O	1579	1586	insulin	insulin	NN	B-NP
O	1586	1587	.	.	.	O

O	1588	1594	Bailie	Bailie	NNP	B-NP
O	1595	1598	and	and	CC	I-NP
O	1599	1609	colleagues	colleague	NNS	I-NP
O	1610	1618	reported	report	VBD	B-VP
O	1619	1633	pharmaceutical	pharmaceutical	JJ	B-NP
O	1634	1647	interventions	intervention	NNS	I-NP
O	1648	1651	for	for	IN	B-PP
O	1652	1660	diabetes	diabetes	NN	B-NP
O	1661	1669	patients	patient	NNS	I-NP
O	1670	1672	in	in	IN	B-PP
O	1673	1679	remote	remote	JJ	B-NP
O	1680	1690	Aboriginal	Aboriginal	JJ	I-NP
O	1691	1702	communities	community	NNS	I-NP
O	1703	1705	in	in	IN	B-PP
O	1706	1709	the	the	DT	B-NP
O	1710	1718	Northern	Northern	JJ	I-NP
O	1719	1728	Territory	Territory	NN	I-NP
O	1729	1730	[	[	(	O
O	1730	1732	54	54	CD	B-NP
O	1732	1733	]	]	)	O
O	1733	1734	.	.	.	O

O	1735	1741	During	During	IN	B-PP
O	1742	1745	the	the	DT	B-NP
O	1746	1747	3	3	CD	I-NP
O	1747	1748	-	-	HYPH	I-NP
O	1748	1753	years	year	NNS	I-NP
O	1754	1759	study	study	NN	I-NP
O	1760	1766	period	period	NN	I-NP
O	1766	1767	,	,	,	O
O	1768	1770	75	75	CD	B-NP
O	1770	1771	-	-	HYPH	I-NP
O	1771	1773	79	79	CD	I-NP
O	1773	1774	%	%	NN	I-NP
O	1775	1777	of	of	IN	B-PP
O	1778	1788	Aboriginal	Aboriginal	JJ	B-NP
O	1789	1797	patients	patient	NNS	I-NP
O	1798	1802	took	take	VBD	B-VP
B-Organism_subdivision	1803	1807	oral	oral	JJ	B-NP
O	1808	1821	hypoglycaemic	hypoglycaemic	JJ	I-NP
O	1822	1828	agents	agent	NNS	I-NP
O	1828	1829	,	,	,	O
O	1830	1833	and	and	CC	O
O	1834	1835	4	4	CD	B-NP
O	1835	1836	-	-	HYPH	I-NP
O	1836	1837	7	7	CD	I-NP
O	1837	1838	%	%	NN	I-NP
O	1839	1843	used	use	VBN	I-NP
O	1844	1851	insulin	insulin	NN	I-NP
O	1851	1852	.	.	.	O

